Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation
Alessia Perino, Thijs Willem Hendrik Pols, Mitsunori Nomura, Sokrates Stein, Roberto Pellicciari, Kristina Schoonjans
Alessia Perino, Thijs Willem Hendrik Pols, Mitsunori Nomura, Sokrates Stein, Roberto Pellicciari, Kristina Schoonjans
View: Text | PDF
Research Article Immunology

TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation

  • Text
  • PDF
Abstract

The bile acid–responsive G protein–coupled receptor TGR5 is involved in several metabolic processes, and recent studies suggest that TGR5 activation may promote pathways that are protective against diet-induced diabetes. Here, we investigated the role of macrophage-specific TGR5 signaling in protecting adipose tissue from inflammation and associated insulin resistance. Examination of adipose tissue from obese mice lacking macrophage Tgr5 revealed enhanced inflammation, increased chemokine expression, and higher macrophage numbers compared with control obese animals. Moreover, macrophage-specific deletion of Tgr5 exacerbated insulin resistance in obese animals. Conversely, pharmacological activation of TGR5 markedly decreased LPS-induced chemokine expression in primary macrophages. This reduction was mediated by AKT-dependent activation of mTOR complex 1, which in turn induced the differential translation of the dominant-negative C/EBPβ isoform, liver inhibitory protein (LIP). Overall, these studies reveal a signaling pathway downstream of TGR5 that modulates chemokine expression in response to high-fat diet and suggest that targeting this pathway has the potential to be therapeutically exploited for prevention of chronic inflammatory diseases and type 2 diabetes mellitus.

Authors

Alessia Perino, Thijs Willem Hendrik Pols, Mitsunori Nomura, Sokrates Stein, Roberto Pellicciari, Kristina Schoonjans

×

Figure 3

LysM-Cre Tgr5fl/fl mice display impaired insulin responsiveness.

Options: View larger image (or click on image) Download as PowerPoint
LysM-Cre Tgr5fl/fl mice display impaired insulin responsiveness.
(A) Bod...
(A) Body weight curves of Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 12 weeks. n = 12 per group. (B) Body composition (fat and lean mass) of Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice, determined by EchoMRI. n = 12 per group. (C) Left: Blood glucose levels during ITT (insulin; 0.75 U/kg) in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 10 weeks. Right: Average AUC. n = 12 per group. (D) Left: Plasma insulin levels during OGTT in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD for 8 weeks. Right: Average AUC. n = 12 per group. (E) Left: Blood glucose levels during OGTT in Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice fed HFD. Right: AUC. n = 12 per group. (F) HOMA-IR of HFD-fed Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice. n = 12 per group. (G–I) Western blot of phospho-AKT (Ser473), total AKT, and HSP90 in (G) liver, (H) gastrocnemius muscle, and (I) eWAT of HFD-fed Tgr5fl/fl and LysM-Cre Tgr5fl/fl mice injected i.p. with vehicle or insulin (1 U/kg; 10 min). Quantitative densitometry of Western blots is also shown. n = 6 per group. Results represent mean ± SEM. *P < 0.05, **P < 0.01 vs. genotype; #P < 0.001 vs. control, 2-tailed Student’s t test or 1- or 2-way ANOVA with Bonferroni post-hoc analysis as appropriate.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts